fenfluramine has been researched along with Cardiovascular Diseases in 14 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this study support the longer term use of dexfenfluramine therapy for patients with chronic obesity." | 9.08 | Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995) |
| "Dexfenfluramine lowers body weight in obese patients with upper and lower body obesity and reduces the cardiovascular risk factors clustering in upper body obesity." | 9.08 | The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy." | 9.07 | Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994) |
| "Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39." | 6.67 | Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992) |
| "The results of this study support the longer term use of dexfenfluramine therapy for patients with chronic obesity." | 5.08 | Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995) |
| "Dexfenfluramine lowers body weight in obese patients with upper and lower body obesity and reduces the cardiovascular risk factors clustering in upper body obesity." | 5.08 | The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy." | 5.07 | Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994) |
| " As a derivative of fenfluramine with an appetite suppressant action, benfluorex is preferentially used in overweight patients." | 3.75 | Fenfluramine-like cardiovascular side-effects of benfluorex. ( Boutet, K; Carlhant-Kowalski, D; Frachon, I; Gut-Gobert, C; Humbert, M; Jobic, Y; Leroyer, C; Simonneau, G; Sitbon, O, 2009) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Dexfenfluramine treatment augments weight and fat loss on a reduced-fat, ad libitum diet, with some evidence for preferential loss of waist fat compared with hip fat." | 2.68 | Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. ( Carmichael, HE; Swinburn, BA; Wilson, MR, 1996) |
| "Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39." | 2.67 | Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992) |
| " Receptorome screening has implicated N-deethylation of fenfluramine and serotonin 5-hydroxy-t-ryptamine 2B receptors in the adverse effects of the drug; subsequent studies corroborated this finding." | 2.43 | Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. ( Roth, BL; Setola, V, 2005) |
| "Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem." | 2.40 | The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (71.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boutet, K | 1 |
| Frachon, I | 1 |
| Jobic, Y | 1 |
| Gut-Gobert, C | 1 |
| Leroyer, C | 1 |
| Carlhant-Kowalski, D | 1 |
| Sitbon, O | 1 |
| Simonneau, G | 1 |
| Humbert, M | 1 |
| Setola, V | 1 |
| Roth, BL | 1 |
| Després, JP | 1 |
| Lemieux, S | 1 |
| Lamarche, B | 1 |
| Prud'homme, D | 1 |
| Moorjani, S | 1 |
| Brun, LD | 1 |
| Gagné, C | 1 |
| Lupien, PJ | 1 |
| O'Connor, HT | 1 |
| Richman, RM | 1 |
| Steinbeck, KS | 1 |
| Caterson, ID | 1 |
| Bremer, JM | 1 |
| Scott, RS | 1 |
| Lintott, CJ | 1 |
| Pfohl, M | 1 |
| Luft, D | 1 |
| Blomberg, I | 1 |
| Schmülling, RM | 1 |
| Swinburn, BA | 1 |
| Carmichael, HE | 1 |
| Wilson, MR | 1 |
| Ditschuneit, HH | 1 |
| Flechtner-Mors, M | 1 |
| Adler, G | 1 |
| Weiser, M | 1 |
| Frishman, WH | 1 |
| Michaelson, MD | 1 |
| Abdeen, MA | 1 |
| Greenway, FL | 1 |
| Ryan, DH | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Curzon, G | 1 |
| Gibson, EL | 1 |
| Kilpatrick, IC | 1 |
| Traut, M | 1 |
| Heal, DJ | 1 |
| Mathus-Vliegen, EM | 1 |
| van de Voorde, K | 1 |
| Kok, AM | 1 |
| Res, AM | 1 |
4 reviews available for fenfluramine and Cardiovascular Diseases
| Article | Year |
|---|---|
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
Topics: Animals; Appetite Depressants; Cardiovascular Diseases; Drug Evaluation, Preclinical; Drug-Related S | 2005 |
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications.
Topics: Adipose Tissue; Cardiovascular Diseases; Fenfluramine; Humans; Hyperlipidemias; Insulin Resistance; | 1995 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo | 1997 |
The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection.
Topics: Appetite; Brain; Cardiovascular Diseases; Fenfluramine; Humans; Phentermine; Selective Serotonin Reu | 1999 |
6 trials available for fenfluramine and Cardiovascular Diseases
| Article | Year |
|---|---|
Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
Topics: Adolescent; Adult; Anthropometry; Body Composition; Body Constitution; Cardiovascular Diseases; Chol | 1995 |
Dexfenfluramine reduces cardiovascular risk factors.
Topics: Apolipoproteins B; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Choleste | 1994 |
Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cardiovascular Diseases; Cholesterol; Female; Fe | 1994 |
Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
Topics: Adipose Tissue; Adult; Aged; Appetite Depressants; Body Composition; Cardiovascular Diseases; Dietar | 1996 |
The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Dise | 1996 |
Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
Topics: Adult; Analysis of Variance; Cardiovascular Diseases; Feeding Behavior; Female; Fenfluramine; Humans | 1992 |
4 other studies available for fenfluramine and Cardiovascular Diseases
| Article | Year |
|---|---|
Fenfluramine-like cardiovascular side-effects of benfluorex.
Topics: Appetite Depressants; Cardiovascular Diseases; Diabetes Mellitus; Female; Fenfluramine; Heart Valve | 2009 |
Contingent fees in mass tort litigation.
Topics: Appetite Depressants; Cardiovascular Diseases; Compensation and Redress; Fees and Charges; Fenfluram | 2006 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release.
Topics: Animals; Brain; Cardiovascular Diseases; Fenfluramine; Male; Monoamine Oxidase; Monoamine Oxidase In | 2001 |